Companies in #BTK Inhibition
Found 1 company operating in this sector.
BeiGene (NASDAQ: BGNE; HKEX: 06160) is a global oncology company developing innovative, affordable therapies for cancer patients worldwide. Best known for Brukinsa (zanubrutinib), a BTK inhibitor approved for multiple B-cell malignancies. Committed $300M in 2026 to expand US manufacturing capacity.